IGF1 and major depressive disorder: In 2016, Bot et al. found that plasma IGF-1 was significantly elevated in MDD patients without Ads, whereas patients who were under Ad treatment had significantly lower IGF-1 than controls, independent of drug type or response to treatment [122].